Capital International Sarl Boosts Stock Position in Intuitive Surgical, Inc. $ISRG

Capital International Sarl grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 107,923 shares of the medical equipment provider’s stock after purchasing an additional 7,111 shares during the quarter. Capital International Sarl’s holdings in Intuitive Surgical were worth $48,266,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital International Ltd. CA lifted its stake in shares of Intuitive Surgical by 0.4% in the 3rd quarter. Capital International Ltd. CA now owns 64,202 shares of the medical equipment provider’s stock valued at $28,713,000 after purchasing an additional 280 shares in the last quarter. Capital International Inc. CA lifted its holdings in Intuitive Surgical by 13.6% in the 3rd quarter. Capital International Inc. CA now owns 61,917 shares of the medical equipment provider’s stock worth $27,691,000 after buying an additional 7,415 shares in the last quarter. Capital Group Investment Management PTE. LTD. boosted its holdings in Intuitive Surgical by 1.0% in the third quarter. Capital Group Investment Management PTE. LTD. now owns 14,021 shares of the medical equipment provider’s stock valued at $6,271,000 after purchasing an additional 136 shares during the last quarter. Legal & General Group Plc grew its position in shares of Intuitive Surgical by 6.3% during the third quarter. Legal & General Group Plc now owns 2,376,714 shares of the medical equipment provider’s stock worth $1,062,938,000 after buying an additional 141,357 shares in the last quarter. Finally, LGT Fund Management Co Ltd. grew its holdings in Intuitive Surgical by 33.1% during the 3rd quarter. LGT Fund Management Co Ltd. now owns 4,077 shares of the medical equipment provider’s stock worth $1,786,000 after acquiring an additional 1,014 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ISRG. Argus lowered their target price on shares of Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. BTIG Research reissued a “buy” rating and set a $616.00 target price on shares of Intuitive Surgical in a research note on Friday, January 23rd. Evercore decreased their price target on Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating for the company in a research note on Friday, January 23rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $714.00 price target on shares of Intuitive Surgical in a research note on Friday, January 9th. Finally, TD Cowen raised shares of Intuitive Surgical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $615.86.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $493.53 on Tuesday. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $603.88. The stock’s 50 day simple moving average is $520.00 and its 200 day simple moving average is $512.68. The company has a market capitalization of $175.27 billion, a price-to-earnings ratio of 62.55, a PEG ratio of 3.78 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The firm had revenue of $2.87 billion during the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the prior year, the company earned $2.21 EPS. The firm’s revenue for the quarter was up 18.8% compared to the same quarter last year. On average, analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Gary S. Guthart sold 24,500 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $530.10, for a total transaction of $12,987,450.00. Following the sale, the director directly owned 3,694 shares of the company’s stock, valued at $1,958,189.40. This represents a 86.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Patricia L. Wadors sold 220 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $499.71, for a total transaction of $109,936.20. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 37,261 shares of company stock worth $19,690,721. Corporate insiders own 0.70% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.